100427-52-9

Basic information

• Product Name: 3-Oxo-butyric acid 2-[(3,3-diphenyl-propyl)-methyl-amino]-1-methyl-ethyl ester
• Synonyms: 3-Oxo-butyric acid 2-[(3,3-diphenyl-propyl)-methyl-amino]-1-methyl-ethyl ester
• CAS NO: 100427-52-9
• Molecular Weight: 367.488
• Mol File: 100427-52-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3-Oxo-butyric acid 2-[(3,3-diphenyl-propyl)-methyl-amino]-1-methyl-ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Oxo-butyric acid 2-[(3,3-diphenyl-propyl)-methyl-amino]-1-methyl-ethyl ester(100427-52-9)
• EPA Substance Registry System: 3-Oxo-butyric acid 2-[(3,3-diphenyl-propyl)-methyl-amino]-1-methyl-ethyl ester(100427-52-9)

Safety Data

• Hazardous Substances Data: 100427-52-9(Hazardous Substances Data)

Upstream product

• 28075-29-8 N-methyl-3,3-diphenylpropylamine 
• 674-82-8 4-methyleneoxetan-2-one 
• 100427-50-7 1-[N-(3,3-diphenylpropyl)-N-methylamino]-2-propanol 

Downstream Products

• 210579-46-7 2-[1-(2,3-Dichloro-phenyl)-meth-(Z)-ylidene]-3-oxo-butyric acid 2-[(3,3-diphenyl-propyl)-methyl-amino]-1-methyl-ethyl ester 
• 732231-81-1 2-[1-(3-Nitro-phenyl)-meth-(Z)-ylidene]-3-oxo-butyric acid 2-[(3,3-diphenyl-propyl)-methyl-amino]-1-methyl-ethyl ester 

Relevant articles and documents

Asymmetric N-(3,3-diphenylpropyl)aminoalkyl esters of 4-aryl-2,6- dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acids with antihypertensive activity

A series of asymmetric 4-aryl-1,4-dihydropyridine-3,5-dicarboxylates characterized by the presence of a 3,3-diphenylpropylamino moiety in one of the ester groups were synthesized. They exhibited remarkable antihypertensive activity in spontaneously hypertensive rats as well as affinity for the 1,4- dihydropyridines binding site labelled by 3H-nitrendipine in the calcium channel. Introduction of this bulky and lipophilic amine confers to the whole series an elevated level of antihypertensive activity and a long duration of action, a structure-dependent modulation of the activity being found only in the subset characterized by the presence of a branched propylene bridge between the ester and the amino groups. The presence of the amino group is essential for oral activity. Out of this series, compound 9u (Rec 15/2375- lercanidipine) was selected for clinical development and obtained marketing authorization as an antihypertensive in several countries.